Clinical Study Of a Micro-Implantable Pulse Generator For The Treatment of Peripheral Neuropathic Pain (COMFORT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05287373 |
Recruitment Status :
Recruiting
First Posted : March 18, 2022
Last Update Posted : February 15, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Peripheral Neuralgia Chronic Pain | Device: Nalu Neurostimulation System for PNS Other: conventional medical management | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 150 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Clinical Study Of a Micro-Implantable Pulse Generator For The Treatment of Peripheral Neuropathic Pain |
Actual Study Start Date : | January 31, 2022 |
Estimated Primary Completion Date : | February 28, 2024 |
Estimated Study Completion Date : | September 30, 2024 |
Arm | Intervention/treatment |
---|---|
Active Comparator: PNS Therapy plus Conventional Medical Management
peripheral nerve stimulator plus conventional medical management
|
Device: Nalu Neurostimulation System for PNS
The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator
Other Name: Nalu PNS Other: conventional medical management Conventional medical management |
Conventional Medical Management
Control arm conventional medical management only
|
Other: conventional medical management
Conventional medical management |
- Effectiveness: Responder rates between groups [ Time Frame: 3-months ]Difference in responder rates between groups. Responder rate is defined as the percent of subjects with 50% or greater pain relief from baseline, based on the BPI-Q5 (NRS).
- Safety: Rate of serious and non-serious adverse events between groups [ Time Frame: 3-months ]Rate of serious and non-serious adverse events between groups
- Responder Rates between groups at 6-months [ Time Frame: 6 months ]Difference in responder rates between groups. Responder rate is defined as the percent of subjects with 50% or greater pain relief from baseline, based on the BPI-Q5 (NRS).
- Responder Rates between groups at 12-months [ Time Frame: 12-months ]Difference in responder rates between groups. Responder rate is defined as the percent of subjects with 50% or greater pain relief from baseline, based on the BPI-Q5 (NRS).
- Functional Outcomes: Change in ODI, BDI, EQ-5D, BPI from baseline [ Time Frame: 3, 6 and 12 months ]Change in patient reported outcomes from baseline between groups
- Safety Assessment [ Time Frame: 6 and 12 months ]Rate of serious and non-serious events
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject is between 18 to 80 years of age at the time of enrollment.
- Subject would have been prescribed PNS therapy regardless of participation in this study; the use of the Nalu device must be on-label.
- Subject has been diagnosed with one or more of the conditions listed below in the low back, shoulder, knee, or foot (including ankle):Post-surgical/post-traumatic peripheral neuralgia including but not limited to pain due to peripheral nerve injury, post-surgical scar formation, nerve entrapment; Mononeuropathy, specified or unspecified or in diseases classified elsewhere; Other neuralgia or neuropathic pain; Osteoarthritic pain.
- Subject has chronic (defined as at least 6 months duration), intractable peripheral neuropathic pain, exclusive of the craniofacial region; any nociceptive pain must be less prominent than the neuropathic pain. Pain should have a predominant neuropathic component as per the investigator's clinical assessment.
- Subject should have a pain score of at least 6, in the target area of pain, as recorded on the BPI-Q5 (NRS) at screening.
- Subject is willing to cooperate with the study requirements including, compliance with the study procedures and completion of all study visits.
- Subject reported stable pain (non-escalating) for 60 days prior to signing informed consent.
- Subject is currently receiving CMM and has had stable pain medication use and dosage for 30 days prior to signing informed consent.
- Subject is psychologically qualified to receive a peripheral nerve stimulator as per the clinician's standard clinical practice and judgment and does not have clinically relevant psychological condition(s) that would interfere with their ability to accurately report outcomes or complete study procedures.
- Subject has demonstrated the ability to appropriately place the adhesive clip in the location where the IPG is most likely to be implanted. Alternatively, subject is able to appropriately use the relief belt and/or limb cuff to keep the Therapy Disc in place.
Exclusion Criteria:
- Subject currently has an active implantable medical device such as a drug pump, spinal cord stimulator, peripheral nerve stimulator, sacral nerve stimulator, deep brain stimulator, and/or cardiac pacemaker.
- Subject has previously failed PNS or Spinal Cord Stimulation (SCS) or Dorsal Root Ganglion (DRG) therapy (trial or permanent implant)
- Pain is completely absent at rest.
- Patient has clinical evidence of complex regional pain syndrome (CRPS), peripheral neuralgia of metabolic origin, post-herpetic neuralgia, biochemical evidence of a metabolic or genetic neuropathy (e.g., Charcot'- Marie- Tooth Disease) or mixed motor/sensory polyneuropathy.
- Subject has a medical condition that would prevent them from participating in the current study per investigator's or medical monitor's judgment.
- Subject has had a successful (≥ 50% pain relief) interventional procedure within the past 3 months to treat the same pain condition(s) being examined in this study including, nerve blocks.
- Uncontrolled depression or uncontrolled psychiatric disorders
- Subject is currently participating in another clinical investigation with an active treatment arm.
- Subject is allergic or sensitive to materials used in the device components including, skin adhesives or does not tolerate the wearable aspect of the device.
- Subject has pending or ongoing legal issues (including unresolved worker's compensation claims or equivalent) or other conflicting secondary gain issues related to their chronic pain condition.
- Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, or progressive peripheral vascular disease that has not been medically corrected.
- Subject has an active systemic infection.
- Subject is unable to read and/or write in English or give informed consent.
- Subject has a life expectancy of less than 1 year.
- Subject has an active malignant neoplasm (metastatic or local) or evidence of paraneoplastic syndrome.
- Subject with uncontrolled diabetes mellitus, showing signs of diabetic neuropathy, as evidenced by a neurological exam and a HbA1c test.
- Subject has evidence of an alcohol or drug dependency within the last 6 months prior to enrollment.
- Subject is pregnant (if female and sexually active, subject must be using a reliable form of birth control, be surgically sterile or be at least 1 year post-menopausal).
- Subject is nursing/breastfeeding.
- Subject is on ≥90 mg-morphine equivalents per 24 hours.
- Subject has undergone an ablative treatment of the target peripheral nerve, or proximal nerve trunk giving rise to the target nerve, or dorsal roots (and DRGs) that ultimately make up the target nerve. No ablative procedures directed at the spinal cord, dorsal roots, or peripheral nerve(s) being treated in the study. To note, subjects who have undergone RF ablation of the dorsal rami, cool pulsed RF of the facet innervation may be considered for enrollment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05287373
Contact: Shilpa Kottalgi, BDS, MAS | 760 827 6467 | skottalgi@nalumed.com |
United States, Arizona | |
Arizona Pain Specialists | Recruiting |
Scottsdale, Arizona, United States, 85258 | |
Contact: Clinical Research Coordinator | |
United States, Colorado | |
Denver Back Pain Specialists | Recruiting |
Greenwood Village, Colorado, United States, 80111 | |
Contact: Clinical Research Coordinator | |
United States, District of Columbia | |
International Spine, Pain and Performance Center | Recruiting |
Washington, District of Columbia, United States, 20006 | |
Contact: Clinical research coordinator | |
United States, Texas | |
Institute of Precision Pain Medicine | Recruiting |
Corpus Christi, Texas, United States, 78414 | |
Contact: Clinical Research Coordinator | |
United States, Washington | |
Northwest Pain Care | Recruiting |
Spokane, Washington, United States, 99201 | |
Contact: Clinical Research Coordinator |
Study Director: | Patrick Martin | Nalu Medical |
Responsible Party: | Nalu Medical, Inc. |
ClinicalTrials.gov Identifier: | NCT05287373 |
Other Study ID Numbers: |
NAL-01-2021-US |
First Posted: | March 18, 2022 Key Record Dates |
Last Update Posted: | February 15, 2023 |
Last Verified: | February 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
PNS Peripheral nerve stimulation mIPG peripheral nerve stimulator |
Neuralgia Chronic Pain Pain Neurologic Manifestations |
Peripheral Nervous System Diseases Neuromuscular Diseases Nervous System Diseases |